ALK and neuroblastoma: Importantly, in patients reaching the maintenance treatment phase with dinutuximab beta in the HR-NBL1/SIOPEN trial, the presence of an ALK alteration was still associated with poorer survival, thus strongly suggesting that integration of ALK-targeted therapy is warranted throughout all treatment phases of modern-era HR-NB therapy.